Characteristics of novel anticoagulants and potential economic implications

American Journal of Managed Care

Volumn 17, Issue 1, 2011, Pages S27-S32

  Nutescu, Edith ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; N ((2 (((4 (AMINOIMINOMETHYL)PHENYL)AMINO)METHYL) 1 METHYL 1H BENZIMIDAZOL 5 YL)CARBONYL) N 2 PYRIDINYL BETA ALANINE; N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-BETA-ALANINE; RIVAROXABAN; THIOPHENE DERIVATIVE; VITAMIN K GROUP;

COST CONTROL; DRUG ANTAGONISM; ECONOMICS; HEALTH CARE COST; HUMAN; PATIENT COMPLIANCE; REVIEW; UNITED STATES; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; COST SAVINGS; HEALTH CARE COSTS; HUMANS; MEDICATION ADHERENCE; MORPHOLINES; THIOPHENES; UNITED STATES; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 80052077041     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Hawkins D. Pharmacoeconomics of thrombosis management. Pharmacotherapy. 2004;24(7 pt 2):95S-99S.
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6 suppl):381S-453S.
3. Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm. 2001;58(suppl 2):S4-S13.
4. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I22-I30.
5. Kahn SR. Frequency and determinants of the postthrombotic syndrome after venous thromboembolism. Curr Opin Pulm Med. 2006;12(5):299-303.
6. Baser O. Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplasty. Am J Manag Care. 2011;17:S6-S8.
7. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007;89(6):799-807.
8. Merli G. Quality improvement program: advancement of hospital venous thromboembolism–free zones. Am J Manag Care. 2011;17:S9-S14.
9. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly. 2009;139(5-6):60-64.
10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
11. Cutler DM, Everett W. Thinking outside the pillbox - medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553-1555.
12. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008;4(3):673-681.
13. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/ lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9(3):164-176.
14. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010;44(6):1061-1071.
15. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
16. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
17. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
18. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-1680.
19. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949-956.
20. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-2185.
21. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1-9.
22. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604.
23. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-815.
24. de Lissovoy G, Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. Am J Manag Care. 2002;8(12):1082-1088.
25. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med. 1998;158(18):2001-2003.
26. Lin PJ. Reviewing the reality: why we need to change. Eur Heart J Suppl. 2005;7(suppl E):E15-E20.
27. Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes. 2009;2(6):591-597.
28. Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ. 2007;176(11):1589-1594.
29. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008;179(3):235-244.
30. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6 suppl):160S-198S.
31. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother. 2005;39(3):446-451.
32. Hamby L, Weeks WB, Malikowski C. Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic. Eff Clin Pract. 2000;3(4):179-184.
33. Bauer KA. New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;7(1):1-8.
34. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-1106.
35. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):188S-203S.
36. Lovenox® (enoxaparin sodium) Prescribing Information. sanofi-aventis US LLC, Bridgewater, NJ; 2009. http://products.sanofi-aventis.us/lovenox/lovenox.pdf. Accessed October 19, 2010.
37. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64(7):956-967.
38. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
39. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.
40. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
41. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295.
42. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22.
43. Azizi M, Veyssier-Belot C, Alhenc-Gelas M, et al. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br J Clin Pharmacol. 1995;40(6):577-584.
44. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010;103(3):572-585.
45. Dunbar MR, Upadhyay PK, Karthikeyan S. The use of warfarin as thromboprophylaxis for lower limb arthroplasty. Ann R Coll Surg Engl. 2008;90(6):500-503.
46. Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm. 2002;59(18):1750-1754.
47. Oster G, Ollendorf DA, Vera-Llonch M, Hagiwara M, Berger A, Edelsberg J. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother. 2004;38(3):377-382.
48. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8):943-953.
49. Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health. 2003;6(1):59-74.
50. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106(8):2921-2922.
51. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715.
52. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9):2937-2941.
53. Warkentin TE, Greinacher A. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? Chest. 2007;132(4):1108-1110.
54. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy. 2006;26(10):1438-1445.
55. Francis CW. New issues in oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2008;259-265.
56. Dentali F, Crowther MA. Management of excessive anticoagulant effect due to vitamin K antagonists. Hematology Am Soc Hematol Educ Program. 2008;266-270.
57. Brotman DJ, Jaffer AK, Hurbanek JG, Morra N. Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. Thromb Haemost. 2004;92:1012-1017.
58. Deitelzweig SB, McKean SC, Amin AN, et al. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med. 2008;75(suppl 3):S27-S36.
59. Saunders ME, Grant RE. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. J Natl Med Assoc. 1998;90:677-680.
60. Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm. 2004;10(2):159-165.
61. Chambers S, Chadda S, Plumb JM. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. Int J Lab Hematol. 2010;32(4):427-442.
62. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997;157(3):289-294.
63. Nutescu EA. Antithrombotic therapy for the treatment of venous thromboembolism. Am J Manag Care. 2003;9(5 suppl):S103-S114.
64. Knight KK, Wong J, Hauch O, Wygant G, Aguilar D, Ofman JJ. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health. 2005;8(3):191-200.
65. Kwong LM. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. Am J Manag Care. 2011;17:S22-S26.
66. Wilson SJ, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ. 2003;169(4):293-298.
67. Preparing for the post-warfarin generation of antithrombotics. Am J Manag Care. 2004;10(10 suppl):S318-S323.
68. Nutescu EA. The future of anticoagulation clinics. J Thromb Thrombolysis. 2003;16(1-2):61-63.
69. Marongiu F, Barcellona D. The future of anticoagulation clinics: a journey to thrombosis centers? Haematologica. 2005;90(3):298.
70. Schulman S. Rivaroxaban in orthopedic surgery-a change of paradigm? Clin Appl Thromb Hemost. 2009;15(6):613-620.
71. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J. 2010;51(2):113-123.
72. Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism – systematic review and adjusted indirect comparison. J Clin Pharm Ther. 2010;35(3):1-14.
73. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics. 2009;27(10):829-846.
74. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009; 338:b1147.
75. Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. BMJ. 2002;325(7369):891-894.
76. Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis. 2010;29(2):182-191.
77. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010;104(1):49-60.
78. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115(1):15-20.
79. Phillips KW, Ansell J. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb Haemost. 2010;103(1):34-39.
80. The economics of anticoagulation: what are the issues? Am J Manag Care. 2004;10(10 suppl):S292-S296.